Proinflammatory stem cell signaling in cardiac ischemia

Antioxidants and Redox Signaling

Volumn 11, Issue 8, 2009, Pages 1883-1896

  Herrmann, Jeremy L ^a   Markel, Troy A ^a   Abarbanell, Aaron M ^a   Weil, Brent R ^a   Wang, Meijing ^a   Wang, Yue ^a   Tan, Jiangning ^a   Meldrum, Daniel R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Van Nuys Medical Science Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR;

CELL SURVIVAL; CELLULAR STRESS RESPONSE; CLINICAL TRIAL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

CELL SURVIVAL; HUMANS; INFLAMMATION; MYOCARDIAL ISCHEMIA; SIGNAL TRANSDUCTION; STEM CELLS; UP-REGULATION;

EID: 67650229928     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2434     Document Type: Review

References (163)

1. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, and Dawn B. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167: 989-997, 2007.
2. Adachi M, Fukuda M, and Nishida E. Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148: 849-856, 2000.
3. Al-Radi OO, Rao V, Li RK, Yau T, and Weisel RD. Cardiac cell transplantation: closer to bedside. Ann Thorac Surg 75:S674-S677, 2003.
4. Alarcon-Vargas D, and Ronai Z. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. JBiol Chem 279: 5008-5016, 2004.
5. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, and Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 425: 968-973, 2003.
6. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW, and Hemmings BA. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phos-phatase inhibitors. Proc Natl Acad Sci U S A 93: 5699-5704, 1996.
7. Assmus B, Fischer-Rasokat U, Honold J, Seeger FH, Fichtlscherer S, Tonn T, Seifried E, Schachinger V, Dim-meler S, and Zeiher AM. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res 100:1234-1241,2007.
8. Barile L, Messina E, Giacomello A, and Marban E. Endogenous cardiac stem cells. Prog Cardiovasc Dis 50: 31-8, 2007.
9. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, and Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114: 763-776, 2003.
10. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, and DeClue JE. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19: 6306-6316, 2000.
11. Bergamin E, Wu J, and Hubbard SR. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure 14: 1285-1292, 2006.
12. Bocker W, Docheva D, Prall WC, Egea V, Pappou E, Rossmann O, Popov C, Mutschler W, Ries C, and Schieker M. IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med 86: 1183-1192, 2008.
13. Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, Haussinger D, Heinrich PC, and Graeve L. LPS and TNFalpha induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 463: 365-370, 1999.
14. Bonizzi G and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288, 2004.
15. Brazil DP, Yang ZZ, and Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29: 233-242, 2004.
16. Brognard J, Sierecki E, Gao T, and Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt iso-forms. Mol Cell 25: 917-931, 2007.
17. Cai Z and Semenza GL. PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 97: 1351-1359,2005.
18. Carmeliet P and Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol 237: 133-158, 1999.
19. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, and Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864, 2004.
20. Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, Liu X, Li Y, Ward CA, Melo LG, and Kong D. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 16: 571-579, 2008.
21. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, and Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278: 1803-1805, 1997.
22. Crisostomo PR, Markel TA, Wang Y, and Meldrum DR. Surgically relevant aspects of stem cell paracrine effects. Surgery 143: 577-581, 2008.
23. Crisostomo PR and Meldrum DR. Stem cell delivery to the heart: clarifying methodology and mechanism. Crit Care Med 35: 2654-2656, 2007.
24. Crisostomo PR, Wang M, Markel TA, Lahm T, Abarbanell AM, Herrmann JL, and Meldrum DR. Stem cell mechanisms and paracrine effects: potential in cardiac surgery. Shock 28: 375-383, 2007.
25. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, and Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism. Am J Physiol Cell Physiol 294: C675-C682, 2008.
26. Dallabrida SM, Ismail N, Oberle JR, Himes BE, and Rupnick MA. Angiopoietin-1 promotes cardiac and skeletal myocyte survival through integrins. Circ Res 96: e8-e24, 2005.
27. Datta SR, Brunet A, and Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927, 1999.
28. Deglurkar I, Mal N, Mills WR, Popovic ZB, McCarthy P, Blackstone EH, Laurita KR, and Penn MS. Mechanical and electrical effects of cell-based gene therapy for ischemic cardiomyopathy are independent. Hum Gene Ther 17: 1144-1151, 2006
29. Detillieux KA, Sheikh F, Kardami E, and Cattini PA. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 57: 8-19, 2003.
30. Dimmeler S, Burchfield J, and Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 28: 208-216, 2008.
31. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, and Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17: 215-224, 2005.
32. Duan HF, Wu CT, Wu DL, Lu Y, Liu HJ, Ha XQ, Zhang QW, Wang H, Jia XX, and Wang LS. Treatment of myo-cardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 8: 467-474, 2003.
33. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, and Greenberg ME. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665, 1997.
34. Eisenberg LM, Burns L, and Eisenberg CA. Hematopoietic cells from bone marrow have the potential to differentiate into cardiomyocytes in vitro. Anat Rec A Discov Mol Cell Evol Biol 274: 870-882, 2003.
35. Elmadbouh I, Haider H, Jiang S, Idris NM, Lu G, and Ashraf M. Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angio-myogenesis in the infarcted myocardium. J Mol Cell Cardiol 42: 792-803, 2007.
36. Emery B, Merson TD, Snell C, Young KM, Ernst M, and Kilpatrick TJ. SOCS3 negatively regulates LIF signaling in neural precursor cells. Mol Cell Neurosci 31: 739-747, 2006.
37. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyaraki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Ko-miya S, and Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924, 1997.
38. Engel FB, Schebesta M, Duong MT, Lu G, Ren S, Madwed JB, Jiang H, Wang Y, and Keating MT. p38 MAP kinase inhibition enables proliferation of adult mammalian cardi-omyocytes. Genes Dev 19: 1175-1187, 2005.
39. Fingar DC and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
40. Fingar DC, Salama S, Tsou C, Harlow E, and Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16:1472-1487, 2002.
41. Forte G, Minieri M, Cossa P, Antenucci D, Sala M, Gnocchi V, Fiaccavento R, Carotenuto F, De Vito P, Baldini PM, Prat M, and Di Nardo P. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 24: 23-33, 2006.
42. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, and Sabatini DM. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16: 1865-1870, 2006.
43. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA, and Zon LI. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci U S A 95: 6881-6886, 1998.
44. Gao F, He T, Wang H, Yu S, Yi D, Liu W, and Cai Z. A promising strategy for the treatment of ischemic heart disease: mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 23: 891-898, 2007.
45. Gao X and Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15:1383-1392, 2001.
46. Garg A and Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16: 1053-1068, 2002.
47. Ghosh S, May MJ, and Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998.
48. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, and Dzau VJ. Paracrine action accounts for marked protection of ische-mic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367-368, 2005.
49. Gnecchi M, He H, Noiseux N, Liang OD, Zhang L, Morello F, Mu H, Melo LG, Pratt RE, Ingwall JS, and Dzau VJ. Evidence supporting paracrine hypothesis for Akt-modi-fied mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20: 661-669, 2006.
50. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, and Johnson RP. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3: 1337-1345, 1997.
51. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, and Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11: 859-871, 2006.
52. Guo Y, He J, Wu J, Yang L, Dai S, Tan X, and Liang L. Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res 39: 179-188, 2008.
53. Guttridge DC, Albanese C, Reuther JY, Pestell RG, and Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785-5799, 1999.
54. Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, Bae JW, Oh BH, Park YB, and Kim HS. Pre-treatment of mes-enchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 51: 933-943, 2008.
55. Haider H and Ashraf M. Bone marrow stem cell transplantation for cardiac repair. Am J Physiol Heart Circ Physiol 288: H2557-H2567, 2005.
56. Haspel RL and Darnell JE Jr. A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1. Proc Natl Acad Sci U S A 96: 10188-10193, 1999.
57. Hayden MS and Ghosh S. Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
58. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20, 2003.
59. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, and Nicola NA. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95: 114-119, 1998.
60. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698, 1999.
61. Huang J and Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190, 2008.
62. 2+ mobilization. Am J Physiol 275:C832-C839, 1998.
63. Imanishi Y, Saito A, Komoda H, Kitagawa-Sakakida S, Miyagawa S, Kondoh H, Ichikawa H, and Sawa Y. Allo-genic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol 44: 662-671, 2008.
64. Inoki K, Li Y, Xu T, and Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17: 1829-1834, 2003
65. Johnson GL and Lapadat R. Mitogen-activated protein ki-nase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
66. Kahn J, Byk T, Jansson-Sjostrand L, Petit I, Shivtiel S, Nagler A, Hardan I, Deutsch V, Gazit Z, Gazit D, Karlsson S, and Lapidot T. Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood 103: 2942-2949, 2004.
67. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC, and Conaway JW. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev 12: 3872-3881, 1998.
68. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, and Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675, 2001.
69. Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, Muguruma Y, Tsuboi K, Itabashi Y, Ikeda Y, Ogawa S, Okano H, Hotta T, Ando K, and Fukuda K. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocar-dial infarction. Blood 104: 3581-3587, 2004.
70. Kim C, Li RK, Li G, Zhang Y, Weisel RD, and Yau TM. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg 83: 640-646, 2007.
71. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, and Sabatini DM. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11: 895-904, 2003.
72. Kim H, Hawley TS, Hawley RG, and Baumann H. Protein tyrosine phosphatase 2 (SHP-2) moderates signaling by gp130 but is not required for the induction of acute-phase plasma protein genes in hepatic cells. Mol Cell Biol 18: 1525-1533, 1998.
73. Kim TK and Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273: 1717-1719, 1996.
74. Kirshenbaum LA. Bcl-2 intersects the NFkappaB signalling pathway and suppresses apoptosis in ventricular myo-cytes. Clin Invest Med 23: 322-330, 2000.
75. Kulik G, Klippel A, and Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phospha-tidylinositol 3-kinase, and Akt. Mol Cell Biol 17: 1595-1606, 1997.
76. Kuwahara K, Saito Y, Kishimoto I, Miyamoto Y, Harada M, Ogawa E, Hamanaka I, Kajiyama N, Takahashi N, Izumi T, Kawakami R, and Nakao K. Cardiotrophin-1 phosphory-lates akt and BAD, and prolongs cell survival via a PI3K-dependent pathway in cardiac myocytes. J Mol Cell Cardiol 32: 1385-1394, 2000.
77. Kyriakis JM and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869, 2001.
78. Lawlor MA and Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114:2903-2910, 2001.
79. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY, Ping B, Huang WC, He X, Hung JY, Lai CC, Ding Q, Su JL, Yang JY, Sahin AA, Hortobagyi GN, Tsai FJ, Tsai CH, and Hung MC. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455, 2007.
80. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, Yoshimura A, Neel BG, Heinrich PC, and Schaper F. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 278: 661-671, 2003.
81. Leonard WJ and O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322, 1998.
82. Li W, Ma N, Ong LL, Nesselmann C, Klopsch C, Ladilov Y, Furlani D, Piechaczek C, Moebius JM, Lutzow K, Lendlein A, Stamm C, Li RK, and Steinhoff G. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 25: 2118-2127, 2007.
83. Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, and Shuai K. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 95: 10626-10631, 1998.
84. Liu D, Scafidi J, Prada AE, Zahedi K, and Davis AE 3rd. Nuclear phosphatases and the proteasome in suppression of STAT1 activity in hepatocytes. Biochem Biophys Res Commun 299: 574-580, 2002.
85. Liu XB, Jiang J, Gui C, Hu XY, Xiang MX, and Wang JA. Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway. Acta Pharmacol Sin 29: 815-822, 2008.
86. Loboda A, Jazwa A, Grochot-Przeczek A, Rutkowski AJ, Cisowski J, Agarwal A, Jozkowicz A, and Dulak J. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 10: 1767-1812, 2008.
87. Lu W, Gong D, Bar-Sagi D, and Cole PA. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 8: 759-769, 2001.
88. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, Kishimoto T, Barbieri G, Pellegrini S, Sendtner M, Heinrich PC, and Horn F. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263: 89-92, 1994.
89. Ma D, Bai X, Guo S, and Jiang Y. The switch I region of Rheb is critical for its interaction with FKBP38. J Biol Chem 283:25963-25970, 2008.
90. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, and Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of in-farcted hearts. Nat Med 9: 1195-1201, 2003.
91. Markel TA, Crisostomo PR, Wang M, Herring CM, Lahm T, Meldrum KK, Lillemoe KD, Rescorla FJ, and Meldrum DR. Iron chelation acutely stimulates fetal human intestinal cell production of IL-6 and VEGF while decreasing HGF: the roles of p38, ERK, and JNK MAPK signaling. Am J Physiol Gastrointest Liver Physiol 292: G958-G963, 2007.
92. Matsubayashi Y, Fukuda M, and Nishida E. Evidence for existence of a nuclear pore complex-mediated, cytosol-independent pathway of nuclear translocation of ERK MAP kinase in permeabilized cells. JBiolChem 276: 41755-41760, 2006.
93. Matsumoto R, Omura T, Yoshiyama M, Hayashi T, Inamoto S, Koh KR, Ohta K, Izumi Y, Nakamura Y, Akioka K, Kitaura Y, Takeuchi K, and Yoshikawa J. Vascular endo-thelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 25: 1168-1173, 2005.
94. Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, and Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113: 1287-1294, 2006.
95. Michlewski G, Sanford JR, and Caceres JF. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol Cell 30: 179-189, 2008.
96. Murakami M, Hibi M, Nakagawa N, Nakagawa T, YasukawaK,YamanishiK,TagaT, andKishimotoT.IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260: 1808-1810, 1993.
97. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, and Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929, 1997.
98. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Met-calf D, Hilton DJ, Nicola NA, and Baca M. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.Proc Natl Acad Sci U S A 97: 6493-6498, 2000.
99. Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, Dzau VJ, and Pratt RE. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 14: 840-850,2006.
100. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, and Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461-15464, 2003.
101. Nygren JM, Jovinge S, Breitbach M, Sawen P, Roll W, Hescheler J, Taneera J, Fleischmann BK, and Jacobsen SE. Bone marrow-derived hematopoietic cells generate cardio-myocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10: 494-501, 2004.
102. Ogawa M, Tajima F, Ito T, Sato T, Laver JH, and Deguchi T. CD34 expression by murine hematopoietic stem cells: developmental changes and kinetic alterations. Ann N Y Acad Sci 1938: 139-145, 2001.
103. Otterbein LE, Soares MP, Yamashita K, and Bach FH. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24: 449-455, 2003.
104. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.
105. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, and Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 77: 134-142, 2008.
106. Pearson RB, Dennis PB, Han JW, Williamson NA, Kozma SC, Wettenhall RE, and Thomas G. The principal target of rapamycin-induced p70s6k inactivation is a novel phos-phorylation site within a conserved hydrophobic domain. EMBO J 14: 5279-5287, 1995.
107. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV, Mesquita CT, Belem L, Vaughn WK, Rangel FO, Assad JA, Carvalho AC, Branco RV, Rossi MI, Dohmann HJ, and Willerson JT. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110(11 suppl 1): II213-II218, 2004.
108. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, and Marshak DR. Multilineage potential of adult human mes-enchymal stem cells. Science 284: 143-147, 1999.
109. Raman M, Chen W, and Cobb MH. Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112, 2007.
110. Ranganathan A, Yazicioglu MN, and Cobb MH. The nuclear localization of ERK2 occurs by mechanisms both independent of and dependent on energy. J Biol Chem 281:15645-15652, 2006.
111. Reiling JH and Sabatini DM. Stress and mTORture signaling. Oncogene 25: 6373-6383, 2006.
112. Reszka AA, Seger R, Diltz CD, Krebs EG, and Fischer EH. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci U S A 92: 8881-8885, 1995
113. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, and Hong Y. Heart disease and stroke statistics: 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-e146, 2008.
114. Rota M, Kajstura J, Hosoda T, Bearzi C, Vitale S, Esposito G, Iaffaldano G, Padin-Iruegas ME, Gonzalez A, Rizzi R, Small N, Muraski J, Alvarez R, Chen X, Urbanek K, Bolli R, Houser SR, Leri A, Sussman MA, and Anversa P. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 104: 17783-17788, 2007.
115. Ryan JM, Barry FP, Murphy JM, and Mahon BP. Me-senchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2: 8, 2005.
116. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, and Wagner EF. Distinct roles for JNK1 and JNK2 in reg-ulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 15: 713-725, 2004.
117. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, and Sabatini DM. Prolonged ra-pamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol Cell 22: 159-168, 2006
118. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005.
119. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA, Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyro-sine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4: 339-351, 1999.
120. Sato T, Laver JH, and Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 94: 2548-2554, 1999.
121. Sauer H, Bekhite MM, Hescheler J, and Wartenberg M. Redox control of angiogenic factors and CD31-positive vessel-like structures in mouse embryonic stem cells after direct current electrical field stimulation. Exp Cell Res 304:380-390, 2005.
122. Scarabelli TM, Knight R, Stephanou A, Townsend P, Chen-Scarabelli C, Lawrence K, Gottlieb R, Latchman D, and Narula J. Clinical implications of apoptosis in ischemic myocardium. Curr Probl Cardiol 31: 181-264, 2006.
123. Schaper F, Gendo C, Eck M, Schmitz J, Grimm C, Anhuf D, Kerr IM, and Heinrich PC. Activation of the protein tyro-sine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J 335:557-565, 1998.
124. Shi Y and Gaestel M. In the cellular garden of forking paths: how p38 MAPKs signal for downstream assistance. Biol Chem 383: 1519-1536, 2002.
125. Shiojima R and Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20: 3347-3365, 2006.
126. Solt LA, Madge LA, Orange JS, and May MJ. Interleukin-1-induced NF-kappaB activation is NEMO-dependent but does not require IKKbeta. J Biol Chem 282: 8724-8733, 2007.
127. Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu Z, Chung JH, Kim BS, Lee H, Joung B, Park S, Choi D, Jang Y, Chung NS, Yoo KJ, and Hwang KC. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 19: 402-407, 2005.
128. Spiegelstein D, Kim C, Zhang Y, Li G, Weisel RD, Li RK, and Yau TM. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am J Physiol Heart Circ Physiol 293:H3311-H3316, 2007.
129. Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, and Yancopoulos GD. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263: 92-95, 1994.
130. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA and Hilton DJ. A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921, 1997.
131. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, and Hawkins PT. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphos-phate- dependent activation of protein kinase B. Science 279:710-714, 1998.
132. Sun L, Cui M, Wang Z, Feng X, Mao J, Chen P, Kangtao M, Chen F, and Zhou C. Mesenchymal stem cells modified with angiopoietin-1 improve remodeling in a rat model of acute myocardial infarction. Biochem Biophys Res Commun 357: 779-784, 2007.
133. Symes A, Stahl N, Reeves SA, Farruggella T, Servidei T, Gearan T, Yancopoulos G, and Fink JS. The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neuro-trophic factor induction of gene expression. Curr Biol 7: 697-700, 1997.
134. Takada Y, Singh S, and Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 279: 15096-15104, 2004.
135. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, and Phillips MI. Improved graft mesenchymal stem cell survival in is-chemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 46: 1339-1350, 2005.
136. Terrell AM, Crisostomo PR, Wairiuko GM, Wang M, Morrell ED, and Meldrum DR. Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart. Shock 26: 226-234, 2006.
137. Thiel S, Behrmann I, Dittrich E, Muys L, Tavernier J, Wijdenes J, Heinrich PC, and Graeve L. Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway. Biochem J 330: 47-54, 1998.
138. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, and McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514, 1999.
139. Toma C, Pittenger MF, Cahill KS, Byrne BJ, and Kessler PD. Human mesenchymal stem cells differentiate to a cardio-myocyte phenotype in the adult murine heart. Circulation 105: 93-98, 2002.
140. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, Shiraishi I, Zias E, Walsh K, Rosenzweig A, Sussman MA, Urbanek K, Nadal-Ginard B, Kajstura J, Anversa P, and Leri A. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ Res 94: 514-524, 2004.
141. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, and Davis RJ. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874, 2000.
142. Uchiyama T, Engelman RM, Maulik N, and Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 109: 3042-3049,2004.
143. Uemura R, Xu M, Ahmad N, and Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 98: 1414-1421, 2006.
144. Vulapalli SR, Chen Z, Chua BH, Wang T, and Liang CS. Cardioselective overexpression of HO-1 prevents I/R-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol 283: H688-H694, 2002.
145. Wang M, Crisostomo PR, Herring C, Meldrum KK, and Meldrum DR. Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 291: R880-R884, 2006.
146. Wang M, Sankula R, Tsai BM, Meldrum KK, Turrentine M, March KL, Brown JW, Dinarello CA, and Meldrum DR. P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock 21: 170-174, 2004.
147. Wang M, Tsai BM, Turrentine MW, Mahomed Y, Brown JW, and Meldrum DR. p38 mitogen activated protein ki-nase mediates both death signaling and functional depression in the heart. Ann Thorac Surg 80: 2235-2241, 2005.
148. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, Fu XY, and Meldrum DR. Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling. Am J Physiol Heart Circ Physiol 293:H2101-H2108, 2007.
149. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, Fu XY, and Meldrum DR. STAT3 mediates bone marrow mesenchymal stem cell VEGF production. J Mol Cell Cardiol 42: 1009-1015, 2007.
150. Wang Y, Haider HK, Ahmad N, Xu M, Ge R, and Ashraf M. Combining pharmacological mobilization with intra-myocardial delivery of bone marrow cells over-expressing VEGF is more effective for cardiac repair. J Mol Cell Cardiol 40: 736-745, 2006.
151. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, and Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 13: 276-288, 1993.
152. Widera D, Mikenberg I, Elvers M, Kaltschmidt C, and Kaltschmidt B. Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF-kappaB signaling. BMC Neurosci 7: 64, 2006.
153. Wijayanti N, Huber S, Samoylenko A, Kietzmann T, and Immenschuh S. Role of NF-kappaB and p38 MAP kinase signaling pathways in the lipopolysaccharide- dependent activation of heme oxygenase-1 gene expression. Antioxid Redox Signal 6: 802-810, 2004.
154. Yamada Y, Yokoyama S, Wang XD, Fukuda N, and Takakura N. Cardiac stem cells in brown adipose tissue express CD133 and induce bone marrow nonhematopoietic cells to differentiate into cardiomyocytes. Stem Cells 25:1326-1333, 2007.
155. Yamamoto T, Sekine Y, Kashima K, Kubota A, Sato N, Aoki N, and Matsuda T. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Bio-chem Biophys Res Commun 297: 811-817, 2002.
156. Yau TM, Kim C, Li G, Zhang Y, Weisel RD, and Li RK. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 112(9 suppl): I123-II28, 2005.
157. Yeoh GC, Ernst M, Rose-John S, Akhurst B, Payne C, Long S, Alexander W, Croker B, Grail D, and Matthews VB. Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology 45: 486-494, 2007.
158. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, and Buck DW. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
159. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, Xu M, Zhu Y, Ashraf M, and Wang Y. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. J Mol Cell Cardiol 44: 281-292, 2008.
160. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, Kile BJ, Keni SB, Alexander WS, Metcalf D, Hilton DJ, Nicola NA, and Baca M. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 96: 2071-2076, 1999.
161. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, Koc ON, and Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21:3197-3207, 2007.
162. Zhang N, Mustin D, Reardon W, Almeida AD, Mozdziak P, Mrug M, Eisenberg LM, and Sedmera D. Blood-borne stem cells differentiate into vascular and cardiac lineages during normal development. Stem Cells Dev 15:17-28,2006.
163. Zohlnhofer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, and Heinrich PC. The hepatic interleukin-6 receptor: down-regulation of the interleukin-6 binding sub-unit (gp80) by its ligand. FEBS Lett 306: 219-222, 1992.